M&T Bank quarterly profit rises on higher fees, lower rainy day funds
Shares of the Buffalo, New York-based regional bank, which also set aside lower buffers in the quarter for potential losses on loans, were up 1.4% in premarket trading.
U.S. consumers have remained healthy despite heightened uncertainty from tariffs and geopolitical turmoil.
Executives across industries have noted that sentiment is improving, with businesses seeking further clarity on trade and monetary policy before making investments. Dealmaking has also picked up, anchored by tech-heavy initial public offerings and multi-billion dollar buyouts.
M&T's total noninterest income rose to $683 million in the second quarter from $584 million in the year ago. This reflected a 23% increase in mortgage banking revenues, helped by higher residential mortgage loan servicing income.
Trust income rose to $182 million from $170 million.
The lender's provision for credit losses fell to $125 million from $150 million a year ago.
M&T has historically had greater exposure to commercial real estate (CRE) loans compare with other regional banking peers.
The lender has been trying to reduce the concentration of CRE loans on its balance sheet as the sector continues to struggle amid elevated interest rates and a dour macroeconomic outlook.
Analysts believe the bank's loan growth will increasingly start pulling ahead of peers as CRE headwinds fade. The company recently said CRE forms about 19% of its balance sheet.
M&T's average CRE loans fell 19.5% to $25.33 billion in the quarter, while average consumer loans rose to $25.35 billion from $21.97 billion in the year-ago period.
Its net income rose to $679 million, or $4.24 per share, in the three months ended June 30 from $626 million, or $3.73 per share, a year ago.
Melden Sie sich an, um Ihr Portfolio aufzurufen.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 minutes ago
- Yahoo
Trailhead Biosystems® Expands Human Cell-Based Product Line with iPSC-Derived A9 Dopaminergic Neurons
BEACHWOOD, Ohio, July 23, 2025 /CNW/ -- Trailhead Biosystems, Inc. ( a biotechnology company pioneering the creation of induced pluripotent stem cell (iPSC)-derived human cells at scale for drug discovery and cell therapy, introduces TrailBio® A9 Dopaminergic Neurons, a powerful new tool available off-the-shelf for studying Parkinson's disease and other neurodegenerative conditions. A9 dopaminergic neurons play a critical role in movement regulation and are disproportionately affected in Parkinson's disease. Historically, researchers have lacked access to viable human models, relying instead on animal studies with limited relevance. With TrailBio® A9 Dopaminergic Neurons, scientists now have a human-specific platform to investigate disease mechanisms, develop therapies and accelerate drug discovery. "TrailBio® A9 Dopaminergic Neurons open new possibilities for Parkinson's research," said Dr. Jan Jensen, Chief Scientific Officer, Chief Technology Officer and founder of Trailhead Biosystems. "These cells enable researchers to study the vulnerabilities of A9 neurons, helping drive progress toward more effective treatments." "For decades, the lack of human A9 neurons has limited our ability to truly understand Parkinson's disease," added Dr. Nooshin Amini, Scientific Director at Trailhead Biosystems. "Now, with TrailBio® A9 Dopaminergic Neurons, researchers can directly study the exact cells that are most affected, offering hope for groundbreaking insights and future therapies." About Trailhead Biosystems Trailhead Biosystems, Inc. is pioneering an informatics-based approach in regenerative medicine and drug discovery. Founded in 2015 as a spinout from the Cleveland Clinic and Case Western Reserve University, Trailhead emerged from the research of CSO/CTO and founder Dr. Jan Jensen. Trailhead creates optimized human cells at scale with its proprietary High-Dimensional Design-of-Experiments (HD-DoE®) platform, integrating advanced mathematical modeling with high-throughput robotic manufacturing. This innovative system allows Trailhead to develop specialized, high-quality iPSC-derived human cells for drug discovery and cell-based therapies. TrailBio® A9 Dopaminergic Neurons represent one of many specialized human cell types emerging from this platform, with additional cell models expected in the near future. Learn more about Trailhead Biosystems, TrailBio® A9 Dopaminergic Neurons and HD-DoE® at For more information, please contact: Tim Mauk, Corporate CommunicationsTrailhead BiosystemsEmail: info@ View original content to download multimedia: SOURCE Trailhead Biosystems Inc View original content to download multimedia:
Yahoo
2 minutes ago
- Yahoo
S&P 500 Is Getting More Bitcoin Exposure as Block Joins the Club
Block, Jack Dorsey's Bitcoin-focused payments company, is set to join the S&P 500 on Wednesday, a milestone moment for both the company and and foray further into crypto for the benchmark index. Block (XYZ), which was rebranded from Square in 2021, is the second blockchain company to join the club after cryptocurrency exchange Coinbase Global (COIN) was added to the index in mid-May. That means index fund investors will get a modest bump in exposure to the world's largest cryptocurrency bitcoin (BTCUSD). The company takes the spot vacated by Hess Corp., which was acquired by Chevron (CVX) in a deal that closed July 18. It's the third addition of the month, following The Trade Desk (TTD) and Datadog (DDOG). Since the announcement of Block's inclusion late Friday, the shares have risen 9%. Block's stock has benefited from an index effect, which refers to directional pressure on stocks when a company is added to, or removed from, the S&P 500 and other indexes. The most recent research report on the matter from S&P Dow Jones Indices, which studied the price impact of index additions and deletions from 1995 to June 2021, showed that it isn't always much of a force. The median excess returns—defined here as the difference between a stock's total return and that of the broader index—of stocks added to the index, measured from the announcement date to the effective date, was about 8% from 1995 to 1999. From 2000 to 2010, that number shrank to 3.6%, and was essentially nonexistent from 2011 to 2021. And even if an index effect shows up ahead of the official inclusion or deletion date, according to a McKinsey study, the premium or discount has a tendency to dissipate within a few months. What's new can get old pretty fast. Read the original article on Investopedia Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 minutes ago
- Yahoo
Texas Instruments shares sink as tariff risks cloud chip demand outlook
(Reuters) -Texas Instruments shares slumped nearly 12% in premarket trading on Wednesday, after its quarterly profit forecast indicated a hit to demand for its analog chips that stoked investor fears of tariff-related disruptions. The dour third-quarter profit forecast contrasts with its earlier hopes for a strong rebound in chip demand, increasing concerns about tariff impacts and tempering investor confidence. In response to analysts' questions on a post-earnings call about whether tariffs were prompting customers to pull in orders and bumping up revenue, TI CEO Haviv Ilan said he "can't rule out the possibility". "(TI's) tone has shifted markedly vs last quarter's call as well as vs management's intra-quarter commentary, with seemingly more caution around the geopolitical and tariff environment," said Bernstein analyst, Stacy Rasgon, adding that the shift "felt somewhat sudden". Chipmakers like TI are not directly affected by Trump's higher tariffs yet, but rising costs for chip-making tools and reduced spending by some customers are starting to have an impact. This was evident in the broader semiconductor industry, with both ASML, the biggest supplier of chip-making equipment globally, and TSMC, the world's biggest chipmaking factory, last week, warned about tariff-related uncertainty. "The impact of tariffs/trade is beginning to emerge and we anticipate a continuation of a slightly weaker than seasonal demand environment as the year progresses due to the impact of tariffs," said analysts at J.P. Morgan. Some analysts also expressed concerns about pressure to TI's margins due to the company's rising investments to expand its U.S. manufacturing footprint. Following the results, at least six brokerages cut price targets on the stock, while three raised, as per data compiled by LSEG. The firm is up about 15%, while peer Analog Devices has gained around 11%, so far this year. TI has a 12-month forward price-to-earnings ratio of 34.66, compared to Analog Devices' 27.64.
